First Time Loading...
B

Biotech Acquisition Co
NASDAQ:BIOT

Watchlist Manager
Biotech Acquisition Co
NASDAQ:BIOT
Watchlist
Price: 10.15 USD Market Closed
Updated: May 2, 2024
Section:
 

Intrinsic Value

Biotech Acquisition Co. operates as a blank check company. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of BIOT.

Key Points:
BIOT Intrinsic Value
Base Case
Not Available
B
Base Case Scenario
What is intrinsic value?

Fundamental Analysis

Beta
Ask me anything about
Biotech Acquisition Co

What unique competitive advantages
does Biotech Acquisition Co hold over its rivals?

What risks and challenges
does Biotech Acquisition Co face in the near future?

Provide an overview of the primary business activities
of Biotech Acquisition Co.

Show all valuation multiples
for Biotech Acquisition Co.

Provide an overview of the primary business activities
of Biotech Acquisition Co.

What unique competitive advantages
does Biotech Acquisition Co hold over its rivals?

What risks and challenges
does Biotech Acquisition Co face in the near future?

Show all valuation multiples
for Biotech Acquisition Co.

Provide P/S
for Biotech Acquisition Co.

Provide P/E
for Biotech Acquisition Co.

Provide P/OCF
for Biotech Acquisition Co.

Provide P/FCFE
for Biotech Acquisition Co.

Provide P/B
for Biotech Acquisition Co.

Provide EV/S
for Biotech Acquisition Co.

Provide EV/GP
for Biotech Acquisition Co.

Provide EV/EBITDA
for Biotech Acquisition Co.

Provide EV/EBIT
for Biotech Acquisition Co.

Provide EV/OCF
for Biotech Acquisition Co.

Provide EV/FCFF
for Biotech Acquisition Co.

Provide EV/IC
for Biotech Acquisition Co.

Compare the intrinsic valuations
of Biotech Acquisition Co and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biotech Acquisition Co against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biotech Acquisition Co compared to its peers.

Compare the P/E ratios
of Biotech Acquisition Co against its peers.

Discuss the investment returns and shareholder value creation
comparing Biotech Acquisition Co with its peers.

Analyze the financial leverage
of Biotech Acquisition Co compared to its main competitors.

Show all profitability ratios
for Biotech Acquisition Co.

Provide ROE
for Biotech Acquisition Co.

Provide ROA
for Biotech Acquisition Co.

Provide ROIC
for Biotech Acquisition Co.

Provide ROCE
for Biotech Acquisition Co.

Provide Gross Margin
for Biotech Acquisition Co.

Provide Operating Margin
for Biotech Acquisition Co.

Provide Net Margin
for Biotech Acquisition Co.

Provide FCF Margin
for Biotech Acquisition Co.

Show all solvency ratios
for Biotech Acquisition Co.

Provide D/E Ratio
for Biotech Acquisition Co.

Provide D/A Ratio
for Biotech Acquisition Co.

Provide Interest Coverage Ratio
for Biotech Acquisition Co.

Provide Altman Z-Score Ratio
for Biotech Acquisition Co.

Provide Quick Ratio
for Biotech Acquisition Co.

Provide Current Ratio
for Biotech Acquisition Co.

Provide Cash Ratio
for Biotech Acquisition Co.

What is the historical Revenue growth
over the last 5 years for Biotech Acquisition Co?

What is the historical Net Income growth
over the last 5 years for Biotech Acquisition Co?

What is the current Free Cash Flow
of Biotech Acquisition Co?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biotech Acquisition Co.

Popular Strategic Analysis Valuation Peer Analysis Profitability Solvency Financials
Financials
Revenue
Operating Income
Net Income
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Balance Sheet Decomposition
Biotech Acquisition Co

231.4m
Assets
13.2m
Liabilities
231.4m
Assets
13.2m
Liabilities
Current Assets 95.3k
Cash & Short-Term Investments 13.2k
Other Current Assets 82.1k
Non-Current Assets 231.3m
Long-Term Investments 231.3m
Other Non-Current Assets 10
Current Liabilities 3.5m
Accrued Liabilities 3.2m
Short-Term Debt 305k
Other Current Liabilities 3.4k
Non-Current Liabilities 9.7m
Other Non-Current Liabilities 9.7m
Efficiency

Earnings Waterfall
Biotech Acquisition Co

Revenue
0 USD
Operating Expenses
-3.7m USD
Operating Income
-3.7m USD
Other Expenses
11.8m USD
Net Income
8m USD
Operating Margin
Net Margin
FCF Margin
ROE
ROA
ROIC
ROCE

Free Cash Flow Analysis
Biotech Acquisition Co

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BIOT Profitability Score
Profitability Due Diligence

Biotech Acquisition Co's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Negative Free Cash Flow
Low ROE
Negative ROIC
Negative Operating Income
35/100
Profitability
Score

Biotech Acquisition Co's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

BIOT Solvency Score
Solvency Due Diligence

Biotech Acquisition Co's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Positive Net Debt
60/100
Solvency
Score

Biotech Acquisition Co's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIOT Price Targets Summary
Biotech Acquisition Co

There are no price targets for BIOT.
BIOT Lowest Forecast
Wall Street Target
Not Available
BIOT Average Forecast
Wall Street Target
Not Available
BIOT Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BIOT Price
Biotech Acquisition Co

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
+4%
5Y 5Y
+5%
10Y 10Y
+5%
Annual Price Range
10.15
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return 1.44%
Standard Deviation of Annual Returns
N/A
Max Drawdown -10%
Shares Statistics
Market Capitalization 291.8m USD
Shares Outstanding 28 750 000
Percentage of Shares Shorted 0.04%

BIOT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Biotech Acquisition Co

Country

United States of America

Industry

N/A

Market Cap

291.8m USD

Dividend Yield

0%

Description

Biotech Acquisition Co. operates as a blank check company. The company is headquartered in New York City, New York. The company went IPO on 2021-01-28. The firm is created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. The firm focuses for a target business in the healthcare sector. The company has no operations and has no revenues.

Contact

NEW YORK
New York City
545 West 25Th Street, 20Th Floor
+18586920539.0

IPO

2021-01-28

Employees

-

Officers

Chairman & CEO
Dr. Michael Shleifer Ph.D.
CFO & Treasurer
Mr. Thomas Fratacci
Chief Operating Officer
Mr. Ivan Jarry
Chief Investment Officer & Director
Mr. Albert F. Hummel M.B.A.

See Also

Summary
BIOT intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIOT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIOT stock valuation using valuation multiples.
Wall Street Estimates
BIOT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIOT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.